Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Fruquintinib + Sintilimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fruquintinib | Fruzaqla | HMPL-013 | VEGFR Inhibitor (Pan) 36 | Fruzaqla (fruquintinib) binds and inhibits VEGFR1/2/3, potentially resulting in reduced cell proliferation and decreased tumor growth (PMID: 25482937, PMID: 31790382). Fruzaqla (fruquintinib) is FDA approved for use in patients with metastatic colorectal cancer who have received prior therapy (FDA.gov). |
Sintilimab | IBI308|Tyvyt | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Sintilimab (IBI308) is a monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in enhanced anti-tumor immune response (PMID: 29300693, PMID: 29900038, PMID: 32656988). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|